Menu

Who we are

We are on a mission to help you to create superior value and optimise healthcare worldwide.

Our experience and expertise across a wide range of therapeutic areas, including orphan and speciality products, has helped us to develop structured methods and approaches to generate solutions for even the toughest pricing and market access challenges. You will get the best open and honest strategic advice as well as practical operational execution from a team that is globally networked with specific expertise across key markets within Europe, USA, Canada, China, and Japan.

Our vision

Inbeeo was founded from a clear bold vision.

We believe in "A world where the value of health technologies is fully realised"

In any given year, there is a $50 billion gap between analysts’ predicted sales for all new life science products launches and their actual sales. At Inbeeo, we believe that alongside scientific challenges, the root cause of this gap is the lack of careful planning for and demonstration of value. This is why we call it “the value gap”.

Our missions

With our vision in mind, we have aligned our services and products to four key mission areas

Asset 1

Help you to price right

All health technologies should be priced according to the value they bring to patients, healthcare systems and society. We have tools and methods to help you to solve that equation.

Asset 2

Help you to understand the data

Understanding inevitably starts with data. We help you collect data and translate this information into insight and action.
Asset 3

Help you to define the strategy

Maximising the value of health technologies requires making the right decisions at the right time. We apply best-in-class strategy development methods tailored to your needs.
Asset 36

Help you to operationalise the value

Even the best strategies will fail without proper execution. We partner with you to translate your asset value and pricing strategy into an operational reality.

Learn more about our services and products.

Asset 10
Asset 10

Our core values

Our core values reflect our growing organisation and how we partner with you to achieve the exceptional results that you are looking for. Our core values are embedded in every interaction and decision we make:
Asset 12
Dedication
We commit ourselves to deliver your project to the highest standards
Asset 13
Innovation
We strive to provide you with new and creative solutions to your individual challenges
Asset 3
Integrity

We never compromise on doing the right thing for our team, partners and wider society

Asset 1
Open-mindedness
We strive to think ‘outside-the-box’, approaching our partnerships and projects with fresh eyes and an open mindset
Asset 2
Passion
We are motivated and inspired by working with you to contribute to the improvement of healthcare worldwide
Asset 8
Growth
We grow as individuals and as one team and we are aligned with our partners on achieving growth for their business and for ours

Our commitments to you

Asset 5
We will provide you with a tailored personal service – not a cookie-cutter approach. Each Market Access journey is unique and should be treated as such.
Asset 5
We genuinely care about each project we undertake and hold ourselves accountable to meet our partner’s needs and goals
Asset 5
Each phase of your project is carefully thought through, planned and designed to ensure the best approach is selected to achieve impactful results
Asset 5
We will give you a clear and transparent price for your project
Asset 5
The people that you meet are the people that do the work
Asset 5
We will get it right first time, on time and on budget

The Inbeeo team

Hervé Lilliu

During a career split between industry and consulting, Hervé has gained a deep understanding of the key challenges faced by innovative life science companies. He has sharpened his tools while holding key leadership positions including Chief Access Officer, Global Marketing Head, and Affiliate President at Pfizer and UCB across 5 geographies in Europe and North America. He is a recognized thought leader in market access and pricing strategy development. He is passionate about creating novel value creation approaches in areas such as rare diseases, ATMPs, and digital therapeutics. Hervé holds a BSc in Data Science and an MSc in Health Economics both from PSL-Paris Dauphine University.

Read more

Max Rex

Max has spent his career helping companies develop pricing and market access strategies for a variety of innovative products, with a particular focus on orphan drugs and gene therapies. He has significant experience working on projects across Europe, North America and Asia. His expertise is in the development of market access strategies for early-stage assets, as well as pricing research and value communication. Before starting his career, Max attended Imperial College London, where he completed both an undergraduate degree in Biochemistry and an MRes in Molecular and Cellular Biosciences.

Read more

Erin Haney

Erin has focused her career on supporting pharmaceutical and biotech companies in the development and launch of health technologies across Europe and North America. She applies her knowledge of health systems and experience in health economics and outcomes research to help clients solve their most challenging value and pricing questions. Her focus lies in executing strategic pricing projects using a variety of techniques, including primary payer research and landscape and analogue analyses. Her experience spans a variety of disease areas, including CNS, autoimmune, and rare diseases. She holds an MPH specializing in Health Services and Systems from Imperial College London and an Honours BSc in Life Sciences from McMaster University, Canada.

Read more

Sarah Kassenaar

Sarah began her career working in stem cell biology research, first in an academic lab exploring gene therapy and regenerative medicines for hearing loss and severe genetic diseases and gene therapies for haematological disorders, in particular sickle cell disease. Since shifted her career to market access, Sarah has gained extensive experience in the delivery of strategic market access and value strategy projects for early ATMPs and pharmaceuticals across Europe and the US. Her specific expertise includes primary research, including interviews, value story testing, surveys and advisory boards, as well as strategy development across therapy areas such as chronic heart failure, Parkinson’s disease and Alzheimer’s disease. She holds a MBA focusing on strategy and marketing from the University of Cambridge, and a BSc (Hons) in Biological Sciences from the University of Guelph 

Read more

Jean-Marc Frybourg

A graduate of ESCP-Europe and holding a Masters in Market Research and Marketing Strategy, Jean-Marc has 30 years of experience in the broader pharmaceutical industry – including biologics and animal health. After 9 years in pharmaceutical marketing, he gained a Masters in Health Economics at Paris Dauphine University in 1995. Since then, Jean-Marc held various Local, Regional and Global positions encompassing pricing and reimbursement, HEOR, health policy, and government affairs (Novartis, Sanofi Pasteur Vaccines, Pfizer, Shire, Merck, Indivior). Jean-Marc brings experience gained over a vast number of pricing and market access challenges ranging from identifying value for early R&D projects, to protecting products from price erosion during late-stage commercialisation.

Read more

Mingkei (John) Lee

John has focused his career in Market Access where he has gained a breadth of pricing and market access experience across US, key European and JAPAC markets, covering disease areas such as oncology, autoimmune diseases and rare diseases. John focuses on global launch pricing, launch sequencing strategy, landscape assessment and economic modelling at Inbeeo. John graduated from University College London (UCL) with a BSc in Biotechnology.

Read more

Sara Cueva Oemer

Sara started her career in Market Intelligence and Strategy where she focused on the support of business strategic decision-making. She now applies this experience to the Market Access field where she focuses on the delivery of value and pricing strategy projects. In her role, she focuses on quantitative and qualitative data analysis and interpretation, as well as survey design and roundtable content creation and organization. She has also conducted research and supported projects focused on the impact of regulatory updates in the EU on the EU HTA landscape. Sara holds an MSc Public Health from the London School of Hygiene and Tropical Medicine and an MA (Hons) Psychology from the University of Edinburgh

Read more

Yigit Ergin

Yigit began his career working at Silicon Valley-based biotech Cantabio, where he supported the commercial development of multiple pipeline projects in oncology and neurodegenerative diseases. He now applies this knowledge when supporting pharmaceutical and biotech companies on value and pricing strategy projects across a range of disease areas across EU and US markets. His expertise lies in executing primary payer research through payer interviews and surveys, as well as constructing landscape assessments and analogue analyses for orphan products. He is also conducting research on emerging HTA trends for products with surrogate outcomes in non-small cell lung cancer. Yigit graduated from University College London (UCL) with a First-Class Bachelor’s Degree in Biomedical Sciences, as well as an MSc in Drug Discovery and Pharmaceutical Management with Distinction. 

Read more

Tania Savant

Tania has focused her career at Inbeeo on the delivery of complex market access strategies and value strategy development for early assets, with a key focus on ATMPs and orphan drugs, across Europe, North America, and Japan. She applies her experience and expertise from her academic years where she conducted research focused on the development of novel gene therapy tools for the treatment of rare neurological disorders. Tania graduated from the University of St Andrews, with a first-class degree in Neuroscience and a MSc from UCL in Clinical Neuroscience.

Read more

Bart Strezelec

Bart has extensive experience in delivering operational projects including international initiatives. His particular focus is process optimization, finance and payments. His specific expertise includes team support, customer data and budget analysis ensuring smooth running of the organization. He graduated from Middlesex University specializing in antiretroviral treatments. 

Read more

Simon Duolé

Simon holds a master’s degree in Public Affairs from Sciences Po Paris, which he obtained in parallel with his Doctorate in Pharmaceutical Sciences. During his double curriculum, he worked in strategy consulting and in the pharmaceutical industry, familiarizing himself with drugs productivity chains with a focus on orphan drugs.
After graduating with a master’s degree in health economics from Paris Dauphine, he held a position in the medico-economics department at Roche, developing an interest in the strategic valuation of health products. Since more than a year he is expanding his skills to help Inbeeo clients finding the right price and strategy for their products in a sustained context of medical innovations.

Read more

Konstantina Malliou-Najjar

Konstantina brings her background in oncology and knowledge of healthcare systems and policies to support Inbeeo’s clients in the execution of primary payer research, landscape and analogue analyses, and strategic pricing projects across a variety of disease areas, including CNS and orphan diseases. Konstantina graduated with distinction from Imperial Business School with an MSc in International Health Management. Prior to this, she undertook a BSc in Biology in National and Kapodistrian University of Athens(NKUA), during which time Konstantina was specialised in the clinical analysis of bladder cancer.

Read more

Olivia Hasson

During her studies at Imperial College London where Olivia gained an MEng degree in Molecular Bioengineering, she undertook modules spanning from image processing to nanotechnologies for cancer therapy to business economics. She now applies her extensive knowledge and analytic skills to support a range of pricing and market access projects across key European markets. Her specific expertise includes conducting analogue analyses, secondary research and content development. 

After graduating with a master’s degree in health economics from Paris Dauphine, he held a position in the medico-economics department at Roche, developing an interest in the strategic valuation of health products. Since more than a year he is expanding his skills to help Inbeeo clients finding the right price and strategy for their products in a sustained context of medical innovations.

Read more

Mara Gerhardt

Mara has an academic background in translational medicine with extensive research experience focusing on understanding the current challenges facing gene therapy reimbursement in the EU5 and potential solutions to overcome these. She now applies this in a commercial setting to support market access strategy in various therapeutic areas, including gene therapies and Parkinson’s disease. At Inbeeo, she focuses on content development, expert sourcing and both primary and secondary research. Mara holds a Masters in Therapeutic Sciences from the University of Cambridge and a Bachelor’s degree in Biomedical Sciences (Hons) from the University of Bath.

Read more
Asset 10

Connect to our experts

Have a question? Want to connect to one of our experts? Have an interesting pricing, reimbursement or Market Access challenge? Then please do get in touch – we would love to hear from you!
Have a question? Want to connect to one of our experts? Have an interesting pricing, reimbursement or Market Access challenge? Then please do get in touch – we would love to hear from you!

Tell us about you or your business,
we will get back to you